Expertise in
19
conditions

Dr. Irene L. Wapnir

General Surgery | Surgical Oncology
300 Pasteur Dr, 
Stanford, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
19
conditions
300 Pasteur Dr, 
Stanford, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Irene Wapnir is a General Surgeon and a Surgical Oncologist in Stanford, California. Dr. Wapnir is highly rated in 19 conditions, according to our data. Her top areas of expertise are Breast Cancer, Angiosarcoma, Inflammatory Breast Cancer, Mastectomy, and Lymphadenectomy.

Her clinical research consists of co-authoring 84 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
General Surgery
Surgical Oncology
Licenses
Surgery in CA
Hospital Affiliations
Stanford Health Care
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

STANFORD HEALTH CARE
300 Pasteur Dr, Stanford, CA 94305

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized Phase II Study Comparing Surgical Excision Versus Neoadjuvant Radiotherapy Followed by Delayed Surgical Excision of Ductal Carcinoma In Situ (NORDIS)
A Randomized Phase II Study Comparing Surgical Excision Versus Neoadjuvant Radiotherapy Followed by Delayed Surgical Excision of Ductal Carcinoma In Situ (NORDIS)
Enrollment Status: Recruiting
Publish Date: May 04, 2025
Intervention Type: Radiation, Procedure
Study Phase: Not Applicable
A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2025
Intervention Type: Other
Study Phase: Not Applicable
Feasibility Study to Evaluate Performance of the LUM Imaging System for Intraoperative Detection of Residual Tumor in Breast Cancer Patients Receiving and Not Receiving Neoadjuvant Therapy
Feasibility Study to Evaluate Performance of the LUM Imaging System for Intraoperative Detection of Residual Tumor in Breast Cancer Patients Receiving and Not Receiving Neoadjuvant Therapy
Enrollment Status: Terminated
Publish Date: January 15, 2025
Intervention Type: Drug, Device
Study Drug: LUM Imaging System used During Surgery
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2024
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival and Frozen Human Tissue Samples
Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival and Frozen Human Tissue Samples
Enrollment Status: Completed
Publish Date: August 03, 2023
A Pilot Study to Assess the Utility of Indocyanine Green™ (IC-GREEN™) SPY Imaging in the Mapping of Arm Draining Lymphatics and Nodes During Sentinel Node Resection With or Without Axillary Dissection in Breast Cancer
A Pilot Study to Assess the Utility of Indocyanine Green™ (IC-GREEN™) SPY Imaging in the Mapping of Arm Draining Lymphatics and Nodes During Sentinel Node Resection With or Without Axillary Dissection in Breast Cancer
Enrollment Status: Completed
Publish Date: December 11, 2017
Intervention Type: Drug, Device
Study Phase: Phase 2
A Phase 1 Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
A Phase 1 Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
Enrollment Status: Completed
Publish Date: March 22, 2017
Intervention Type: Drug
Study Phase: Phase 1
A Feasibility Study of Radiofrequency Identification (RFID) Localization of Breast Lesions
A Feasibility Study of Radiofrequency Identification (RFID) Localization of Breast Lesions
Enrollment Status: Withdrawn
Publish Date: February 02, 2017
Intervention Type: Procedure, Other
Study Phase: Not Applicable
View 9 Less Clinical Trials

84 Total Publications

Breast Tumor-Bed Biopsy for Pathological Complete Response Prediction: The NRG-BR005 Nonrandomized Clinical Trial.
Breast Tumor-Bed Biopsy for Pathological Complete Response Prediction: The NRG-BR005 Nonrandomized Clinical Trial.
Journal: JAMA surgery
Published: May 07, 2025
Similar Doctors
Expertise in
18
conditions
Dr. Julie A. Sosa
Surgical Oncology | General Surgery
Expertise in
18
conditions
Dr. Julie A. Sosa
Surgical Oncology | General Surgery

Ucsf Dept Of Surgery

505 Parnassus Ave, 
San Francisco, CA 
 (27.5 miles away)
415-476-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Julie Sosa is a Surgical Oncologist and a General Surgeon in San Francisco, California. Dr. Sosa is highly rated in 18 conditions, according to our data. Her top areas of expertise are Thyroid Cancer, Papillary Thyroid Cancer, Medullary Thyroid Carcinoma, Thyroidectomy, and Parathyroidectomy.

Expertise in
23
conditions
Dr. Sanziana A. Roman
Surgical Oncology | General Surgery
Expertise in
23
conditions
Dr. Sanziana A. Roman
Surgical Oncology | General Surgery

Ucsf Dept Of Surgery

505 Parnassus Ave, 
San Francisco, CA 
 (27.5 miles away)
415-476-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sanziana Roman is a Surgical Oncologist and a General Surgeon in San Francisco, California. Dr. Roman is highly rated in 23 conditions, according to our data. Her top areas of expertise are Thyroid Cancer, Hyperparathyroidism, Parathyroid Hyperplasia, Thyroidectomy, and Parathyroidectomy.

Laura J. Esserman
Expertise in
8
conditions
Dr. Laura J. Esserman
Surgical Oncology | General Surgery
Expertise in
8
conditions
Dr. Laura J. Esserman
Surgical Oncology | General Surgery

Ucsf Dept Of Surgery

505 Parnassus Ave, 
San Francisco, CA 
 (27.5 miles away)
415-476-1000
Languages Spoken:
English
See accepted insurances

Laura Esserman is a Surgical Oncologist and a General Surgeon in San Francisco, California. Dr. Esserman is highly rated in 8 conditions, according to our data. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Mastectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wapnir's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile